Company intelligence / Profile preview
Hinova Pharmaceuticals Inc.
Chengdu, Sichuan Province, Chinahinovapharma.com ↗
- Ownership
- Public · 688302
- Employees
- ~181
- Development stage
- Other
01
Overview
The company has multiple clinical-stage programs, with HC-1119 (deuterated enzalutamide) having completed Phase III trials for metastatic castration-resistant prostate cancer. HP501 is in Phase II/III for gout, AMC-303 in Phase II for esophageal cancer, HP518 in Phase I/II for prostate cancer, and HP-515 in Phase I for NASH. HP518 received FDA Fast Track Designation for AR-triple negative breast cancer.
- Therapeutic areas
- GastroenterologyOncologyMetabolic DisordersRheumatology
- Modalities
- Small moleculesProteolysis-targeting chimeras (PROTAC)Deuterated drugsSynthetic peptides
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
amcure GmbH (exclusive license agreement for AMC303)
Beyond the preview
Go deeper on Hinova Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hinova Pharmaceuticals Inc..